106 related articles for article (PubMed ID: 8677901)
1. M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder.
Bellmunt J; Ribas A; Albanell J; Bermejo B; Vera R; De Torres JA; Morote J; Lopez-Pacios MA; Banus JM; Rovirosa A; Carulla J; Sole LA
Am J Clin Oncol; 1996 Aug; 19(4):344-8. PubMed ID: 8677901
[TBL] [Abstract][Full Text] [Related]
2. [Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)].
Bellmunt Molins J; Ribas A; Albanell J; Lorente Garín JA; de Torres Mateos JA; Morote Robles J; López Palacios MA; Banús Gassol JM; Casado Cobo S; Eres N; Solé Calvo LA
Arch Esp Urol; 1996 Jun; 49(5):465-72. PubMed ID: 8766083
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial.
Boccardo F; Pace M; Guarneri D; Canobbio L; Curotto A; Martorana G
Cancer; 1994 Apr; 73(7):1932-6. PubMed ID: 8137220
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy.
Bellmunt J; Albanell J; Gallego OS; Ribas A; Vicente P; Carulla J; De Torres J; Morote J; Lopez M; Solé LA
Cancer; 1992 Oct; 70(7):1974-9. PubMed ID: 1525774
[TBL] [Abstract][Full Text] [Related]
7. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
Hagan MP; Winter KA; Kaufman DS; Wajsman Z; Zietman AL; Heney NM; Toonkel LM; Jones CU; Roberts JD; Shipley WU
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):665-72. PubMed ID: 14529770
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
9. Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI).
Ribas A; Bellmunt J; Albanell J; De Torres I; Bermejo B; De Torres JA; Morote J; Gallardo E; Vera R; Carulla J; Sole-Calvo LA
Tumori; 1996; 82(6):554-9. PubMed ID: 9061063
[TBL] [Abstract][Full Text] [Related]
10. Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: long-term followup of a prospective study.
de la Rosa F; Garcia-Carbonero R; Passas J; Rosino A; Lianes P; Paz-Ares L
J Urol; 2002 Jun; 167(6):2413-8. PubMed ID: 11992048
[TBL] [Abstract][Full Text] [Related]
11. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
Kuroda M; Meguro N; Maeda O; Saiki S; Kinouchi T; Usami M; Kotake T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S9-13. PubMed ID: 7527736
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
[TBL] [Abstract][Full Text] [Related]
14. A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Small EJ; Fippin LJ; Ernest ML; Carroll PR
Cancer; 1996 Oct; 78(8):1775-80. PubMed ID: 8859191
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
Kyriakakis Z; Dimopoulos MA; Kostakopoulos A; Karayiannis A; Sofras F; Zervas A; Giannopoulos A; Dimopoulos C
J Urol; 1997 Aug; 158(2):408-11. PubMed ID: 9224313
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of advanced transitional-cell carcinoma of the bladder.
Miller RS; Torti FM
Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829
[TBL] [Abstract][Full Text] [Related]
17. [Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer].
Kawamura N; Matsushita M; Okada T; Ujike T; Nin M; Tsujihata M
Hinyokika Kiyo; 2013 May; 59(5):277-81. PubMed ID: 23719134
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation.
Edelman MJ; Meyers FJ; Miller TR; Williams SG; Gandour-Edwards R; deVere White RW
Urology; 2000 Apr; 55(4):521-5. PubMed ID: 10736495
[TBL] [Abstract][Full Text] [Related]
19. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
[TBL] [Abstract][Full Text] [Related]
20. [Conservative treatment of infiltrating cancer of the bladder: neoadjuvant chemotherapy and radiotherapy].
Prié L; Gaston R; Ferrière JM; Richaud P; Bui BN; Guillou ML
Cancer Radiother; 1998 Apr; 2 Suppl 1():62s-66s. PubMed ID: 9749081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
